Clinical Trial Update: A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study completed in Asian participants evaluated Erdafitinib, a pan-FGFR tyrosine kinase inhibitor, for efficacy in advanced non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Esophageal Cancer
• Non-small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Neoplasm | Phase 2 | Status: COMPLETED